News

Filter

Current filters:

StallergenesOncology

1451 to 1460 of 97252 results

Rigel’s R348 fails to meet endpoints in Ph II dry eye study

13-08-2014

Clinical-stage US drug developer Rigel Pharmaceuticals says that R348, its ophthalmic JAK/SYK inhibitor,…

BiotechnologyDry eye diseasefostamatinibOphthalmicsR118R348ResearchRigel Pharmaceuticals

New Zealand to fund Vidaza and Revlimid

New Zealand to fund Vidaza and Revlimid

13-08-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC says it has approved a proposal for funding…

Celgene Corp.FinancialHealthcareNew ZealandPharmaceuticalPricingRevlimidVidaza

TNI BioTech and Hubei Qianjiang link up on cancer drug development

TNI BioTech and Hubei Qianjiang link up on cancer drug development

13-08-2014

US biotech firm TNI BioTech has signed a supplemental agreement with China’s Hubei Qianjiang Pharmaceutical…

BiotechnologyBusiness FinanceChinaHubeiLicensingOncologyQianjiang PharmaceuticalResearchTNI BioTechUSA

Asia Healthcare Forum identifies challenges ahead for meetings in the sector

Asia Healthcare Forum identifies challenges ahead for meetings in the sector

13-08-2014

The inaugural Healthcare Meetings Forum Asia was over-subscribed on August 1 at Suntec Singapore, an…

Asia-PacificMarkets & MarketingPharmaceuticalRegulationSingapore

Kadcyla’s rejection confirms that NICE must change the way it considers cancer treatment, says analyst

Kadcyla’s rejection confirms that NICE must change the way it considers cancer treatment, says analyst

13-08-2014

“The National Institute for Health and Care Excellence’s recent rejection of Kadcyla, Roche’s latest…

KadcylaOncologyPharmaceuticalPricingRegulationRocheUK

1451 to 1460 of 97252 results

Back to top